2 Top Stocks in Biotech


In 2016, the FDA approved less than half as many new drugs as the previous year. An increasingly strict regulatory environment might not be great for investing in the broad-based, industry tracking iShares Nasdaq Biotechnology ETF The FDA rarely denies new drug or biologic applications outright.



from Biotech News